March 17, 2016

Celldex Therapeutics to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2016

HAMPTON, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company and its collaborating investigators will present seven posters with new clinical and preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.

Highlights include immune response data from the ongoing Phase 1/2 study of varlilumab and nivolumab in multiple solid tumors, the role of gpNMB as a relevant therapeutic target across multiple cancers and a late-breaking poster from the Phase 1 investigator-sponsored study of CDX-301 (Flt3L) in B-cell lymphomas.

The following Celldex-sponsored abstracts have been selected for poster presentations at AACR:

  • Title: Phase 1 results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events

    Date/Time: Monday, April 18, 8:00 a.m. - 12:00 p.m. CDT
    Location: Section 13
    Abstract: CT023

  • Title: Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcoma

    Date/Time: Wednesday, April 20, 8:00 a.m. - 12:00 p.m. CDT
    Location: Section 27
    Abstract: 5032
     
  • Title: IHC and RT-PCR assays for detection of cancer antigen NY-ESO-1 in human tissues

    Date/Time: Monday, April 18, 8:00 a.m. - 12:00 p.m. CDT
    Location: Section 21
    Abstract: 1373
     
  • Title: Development and characterization of novel CD40 antibody agonists for cancer immunotherapy

    Date/Time: Wednesday, April 20, 8:00 a.m. - 12:00 p.m. CDT
    Location: Section 22
    Abstract: 4866

             
The following investigator-sponsored abstracts have been selected for poster presentations at AACR:

  • Title: In situ vaccination of low-grade lymphoma with intratumoral Flt3L and poly-ICLC with low-dose radiotherapy

    Date/Time: Monday, April 18, 8:00 a.m. - 12:00 p.m. CDT
    Location: Section 10
    Abstract: LB-081

  • Title: Targeting GPNMB with 89Zr-CR011 for PET imaging of triple negative breast cancer

    Date/Time: Tuesday, April 19, 1:00 p.m. - 5:00 p.m. CDT
    Location: Section 33
    Abstract: 4209
     
  • Title: Targeting the melanosome: overcoming MAPK-inhibitor resistance in melanoma

    Date/Time: Sunday, April 17, 1:00 p.m. - 5:00 p.m. CDT
    Location: Section 16
    Abstract: 296

About Celldex Therapeutics, Inc.

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.

 

Contact:

Sarah Cavanaugh

Vice President of Investor Relations & Corp Communications

Celldex Therapeutics, Inc.

(781) 433-3161

scavanaugh@celldex.com



Charles Liles

Manager of Investor Relations & Corp Communications

Celldex Therapeutics, Inc.

(781) 433-3107

cliles@celldex.com



Media Contact:



Dan Budwick

Pure Communications, Inc.

(973) 271-6085

dan@purecommunicationsinc.com

Primary Logo

Source: Celldex Therapeutics, Inc.

News Provided by Acquire Media


Close window | Back to top

Copyright 2017 Celldex Therapeutics, Inc.